17-May-2024
No headlines found.
MIMEDX to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 15-May 8:00 AM ET)
MIMEDX Announces First Quarter 2024 Operating and Financial Results
Globe Newswire (Tue, 30-Apr 4:01 PM ET)
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
Globe Newswire (Tue, 16-Apr 8:00 AM ET)
MIMEDX Provides Update on AXIOFILL Request for Designation ("RFD") from FDA
Globe Newswire (Wed, 27-Mar 8:00 AM ET)
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Globe Newswire (Wed, 20-Mar 7:00 AM ET)
MIMEDX Introduces E-Commerce and Account Management Platform
Globe Newswire (Wed, 13-Mar 8:00 AM ET)
MIMEDX Announces Appointment of Two New Independent Directors
Globe Newswire (Mon, 4-Mar 8:00 AM ET)
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Globe Newswire (Wed, 28-Feb 4:01 PM ET)
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
Globe Newswire (Tue, 20-Feb 8:00 AM ET)
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Mimedx Group trades on the NASDAQ stock market under the symbol MDXG.
As of May 17, 2024, MDXG stock price declined to $7.80 with 531,850 million shares trading.
MDXG has a beta of 1.27, meaning it tends to be more sensitive to market movements. MDXG has a correlation of 0.11 to the broad based SPY ETF.
MDXG has a market cap of $1.15 billion. This is considered a Small Cap stock.
Last quarter Mimedx Group reported $85 million in Revenue and $.07 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.03.
In the last 3 years, MDXG stock traded as high as $15.99 and as low as $2.43.
The top ETF exchange traded funds that MDXG belongs to (by Net Assets): IWM, XBI, VTI, VXF, IWN.
MDXG has underperformed the market in the last year with a price return of +30.2% while the SPY ETF gained +30.7%. MDXG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.2% and +4.0%, respectively, while the SPY returned +6.3% and +4.8%, respectively.
MDXG support price is $7.67 and resistance is $8.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDXG stock will trade within this expected range on the day.